M. Ozguroglu Et Al. , "Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.," JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021
Ozguroglu, M. Et Al. 2021. Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15 .
Ozguroglu, M., Sezer, A., Kilickap, S., Gumus, M., Bondarenko, I., Gogishvili, M., ... Turk, H. M.(2021). Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15.
Ozguroglu, Mustafa Et Al. "Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.," JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021
Ozguroglu, Mustafa Et Al. "Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021
Ozguroglu, M. Et Al. (2021) . "Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15.
@article{article, author={Mustafa ÖZGÜROĞLU Et Al. }, title={Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2021}